IL-1 mediates TNF-induced osteoclastogenesis

被引:619
作者
Wei, S [1 ]
Kitaura, H [1 ]
Zhou, P [1 ]
Ross, FP [1 ]
Teitelbaum, SL [1 ]
机构
[1] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA
关键词
D O I
10.1172/JCI200523394
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
TNF-induced receptor activator NF-kappaB ligand (RANKL) synthesis by bone marrow stromal cells is a fundamental component of inflammatory osteolysis. We found that this process was abolished by IL-1 receptor antagonist (IL-1Ra) or in stromal cells derived from type I IL-1 receptor-deficient (IL-1RI-deficient) mice. Reflecting sequential signaling of the cytokines TNF and IL-1, TNF induces stromal cell expression of IL-1 and IL-1RI These data suggest that TNF regulates RANKL expression via IL-1, and, therefore, IL-1 plays a role in TNF-induced periarticular osteolysis. Consistent with this posture, TNF-stimulated osteoclastogenesis in cultures consisting of WT marrow macrophages and stromal. cells exposed to IL-1Ra or in cocultures established with IL-1RI-deficient stromal cells was reduced approximately 50%. The same magnitude of osteoclast inhibition occurred in IL-1RI-deficient mice following TNF administration in vivo. Like TNF, IL-1 directly targeted osteoclast precursors and promoted the osteoclast phenotype in a TNF-independent manner in the presence of permissive levels of RANKL. IL-1 is able to induce RANKL expression by stromal cells and directly stimulate osteoclast precursor differentiation under the aegis of p38 MAPK. Thus, IL-1 mediates the osteoclastogenic effect of TNF by enhancing stromal cell expression of RANKL and directly stimulating differentiation of osteoclast precursors.
引用
收藏
页码:282 / 290
页数:9
相关论文
共 28 条
[1]  
Arend WP, 2002, J RHEUMATOL, V29, P16
[2]  
Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453
[3]  
Badger AM, 2000, ARTHRITIS RHEUM, V43, P175, DOI 10.1002/1529-0131(200001)43:1<175::AID-ANR22>3.0.CO
[4]  
2-S
[5]  
BRENNAN FM, 1989, LANCET, V2, P244
[6]  
Dayer JM, 2002, J RHEUMATOL, V29, P10
[7]   Biologic basis for interleukin-1 in disease [J].
Dinarello, CA .
BLOOD, 1996, 87 (06) :2095-2147
[8]  
DUNNE A, 2003, SCI STKE, V171, P3
[9]   Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].
Feldmann, M ;
Maini, RN .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196
[10]   Bone destruction in arthritis [J].
Gravallese, EM .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 :84-86